PMID- 24873992
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20140625
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 92
IP  - 7
DP  - 2014 Jul
TI  - Differential expression of lipid peroxidation and total antioxidant status in 
      Indian patients with cardiovascular and cerebrovascular disease.
PG  - 592-7
LID - 10.1139/cjpp-2013-0481 [doi]
AB  - Data from studies examining lipid peroxidation as a mechanism involved with 
      hyperhomocysteinemia (HHcy)-induced vascular remodeling in patients with 
      occlusive vascular disease have been contradictory. It has not yet been studied 
      in Indians within the context of atherogenesis. Therefore, we measured the levels 
      of homocysteine (Hcy), malondialdehyde (MDA) as a measure of lipid peroxides 
      (LPOs), and total antioxidant status (TAS) in the serum of 167 patients with 
      occlusive vascular disease [coronary artery disease (CAD) = 43; cerebrovascular 
      disease (CVD) = 82; peripheral vascular disease (PVD) = 42]. Each of these groups 
      was further divided into groups of individuals with or without HHcy. In the case 
      of CAD and CVD, patients with HHcy had significantly higher LPOs than those 
      without HHcy (p = 0.009, 0.001, respectively). TAS was significantly lower in CVD 
      patients with HHcy than in those without (p = 0.014). In patients with CAD or 
      CVD, Hcy directly correlated with LPOs (p = 0.002, 0.001, respectively). Lipid 
      peroxidation is a significant mechanism in HHcy-induced vascular remodeling in 
      CAD and CVD, but not in PVD, probably because it is not relevant in thrombosis 
      (38 of 42 patients of PVD had deep-vein thrombosis). To explain the significantly 
      lower TAS in CVD, we hypothesized that CVD patients present very early with grave 
      symptoms, whereas CAD and PVD occur over a longer period of time. Therefore, when 
      CVD presents, TAS is still overwhelmed by HHcy-induced oxidative stress. Hence, 
      adjuvant therapy with antioxidants would benefit patients with CVD.
FAU - Bhargava, Seema
AU  - Bhargava S
AD  - a Department of Biochemistry, Sir Ganga Ram Hospital, New Delhi 110060, India.
FAU - Ali, Arif
AU  - Ali A
FAU - Kankra, Mamta
AU  - Kankra M
FAU - Das, Sabari
AU  - Das S
FAU - Manocha, Anjali
AU  - Manocha A
FAU - Gupta, Flora
AU  - Gupta F
FAU - Srivastava, Lalit Mohan
AU  - Srivastava LM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140407
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Antioxidants)
RN  - Homocysteinemia
SB  - IM
MH  - Antioxidants/*metabolism
MH  - Cardiovascular Diseases/complications/*metabolism
MH  - Cerebrovascular Disorders/complications/*metabolism
MH  - Humans
MH  - Hyperhomocysteinemia/complications/metabolism
MH  - India
MH  - *Lipid Peroxidation
MH  - Oxidative Stress
OTO - NOTNLM
OT  - hyperhomocysteinemia
OT  - hyperhomocysteinemie
OT  - lipid peroxides
OT  - maladie vasculaire
OT  - malondialdehyde
OT  - malondialdehyde
OT  - peroxydes lipidiques
OT  - total antioxidant status
OT  - vascular disease
OT  - etat antioxydant total
EDAT- 2014/05/31 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/05/31 06:00
PHST- 2014/05/31 06:00 [entrez]
PHST- 2014/05/31 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 10.1139/cjpp-2013-0481 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2014 Jul;92(7):592-7. doi: 10.1139/cjpp-2013-0481. Epub 
      2014 Apr 7.